GLP-1 Questions Answered: Your Top FAQs, Evidence-Based

This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.
Quick answer
The most common GLP-1 questions — what to eat, a missed dose, side effects, how long to take it, plateaus, and muscle loss — have short, evidence-based answers below, each linking to a deeper guide. For anything personal, ask your prescriber.
Starting a GLP-1 like Ozempic, Wegovy, Mounjaro, or Zepbound brings a wave of questions, and the internet answers them inconsistently.
This page is a curated answer hub: the questions people actually ask, each with a concise, sourced answer and a link to the full guide.
It's a map of the whole GLP-1 topic — start here, then go deep where you need to. None of it replaces your clinician; use it to ask better questions at your next visit.
01
What can I eat on a GLP-1?
Because these drugs sharply reduce appetite, the risk shifts from overeating to under-nourishing. The priority is protein at every meal (roughly 20–30 g) to protect muscle, plus fiber-rich foods — vegetables, beans, oats, berries — to ease the constipation that low intake can cause.
Small, slow meals reduce nausea.
There's no forbidden-foods list, but ultra-rich, greasy meals often trigger symptoms. → Go deeper: our data shows GLP-1 users nail protein but miss fiber (GLP-1 Habit Report), and tracking makes the gap visible (GLP-1 tracker app guide).
02
What happens if I miss a dose?
It depends on the medicine, and you should always follow your own label.
For Wegovy (semaglutide) injection, you take a missed dose only if your next scheduled dose is more than 2 days (48 hours) away; otherwise skip it and resume on your normal day (FDA label: Wegovy).
For Zepbound (tirzepatide), you can take a missed dose within 4 days (96 hours); after that, skip it (FDA label: Zepbound).
Never double up.
The Wegovy rule above is the US FDA label wording; the EU and many other countries' Wegovy leaflets say to take the missed dose within 5 days of the day you missed, otherwise skip it — check the leaflet in your own country.
If you miss 2 or more weekly doses in a row, contact your prescriber about how to restart, usually at a lower dose (US Wegovy label).
A tracker that timestamps each shot makes this decision easy. → Go deeper: how to log doses and never guess in the GLP-1 tracker app guide.

03
Which side effects are normal, and which are red flags?
Most side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation, reflux — and usually appear or worsen right after a dose increase, then settle as your body adapts (Cleveland Clinic).
Rare but serious risks include pancreatitis and gallbladder disease; severe or persistent abdominal pain warrants prompt medical care.
Logging symptom, severity, and timing turns "I feel off" into a pattern your doctor can act on. → Go deeper: managing GLP-1 side effects.
04
How long do I stay on a GLP-1?
For most people, GLP-1 therapy for weight management is treated as a long-term, often ongoing medication rather than a short course, because stopping frequently leads to weight regain as appetite returns (Cleveland Clinic — how long to take a GLP-1).
How long is a decision you make with your prescriber based on your goals, response, and tolerance.
Building durable habits alongside the drug is what makes results last if you ever taper off. → Go deeper: staying consistent with streaks and habits.

05
Why did my weight loss plateau?
Plateaus are normal and expected.
As you lose weight, your body reaches a new energy equilibrium at a lower weight and burns fewer calories — this is metabolic adaptation, not the drug "stopping working." Small increases in intake or muscle loss can also flatten the curve.
Watch the multi-week trend, keep protein and activity up, and discuss dose questions with your clinician rather than adjusting on your own. → Go deeper: set a realistic target with the GLP-1 weight-loss calculator.
06
Will I lose muscle on a GLP-1?
Some lean-mass loss is expected with rapid weight loss.
Across GLP-1 trials, the share of lost weight that is lean mass varies widely—from about 15% or less to 40–60% in some studies—and lean mass includes organs, bone and water, not only muscle (Neeland et al., 2024).
You can defend against it with two habits — adequate protein (about 20–30 g per meal) and resistance training two to four times a week.
Protecting muscle protects your metabolism and long-term results. → Go deeper: the GLP-1 tracker app guide covers protein and body-composition tracking.

07
How do I stay consistent when motivation fades?
Consistency is a design problem, not a willpower problem.
Attach a new habit to an existing cue (weigh in after brushing teeth), keep the bar low, and use the "never miss twice" rule so one off day doesn't spiral.
Game elements such as points, levels and social incentives increased daily steps in a randomized trial of adults with overweight and obesity (Patel et al., 2019), and in one study new behaviors took a median of about 66 days to become automatic, with a wide range of 18 to 254 days (Lally et al., 2010). → Go deeper: gamify weight loss with streaks and rewards.
08
How do I get reliable answers between doctor visits?
Stick to primary sources — the FDA label, the manufacturer's site, or a major clinic — and be wary of forums and AI-generated blogs for anything medical.
An AI health assistant built into your tracking app can answer routine, general questions instantly and point you to your own logged data, which is handy for the small stuff.
But it is not a clinician: anything about your dose, symptoms, or safety belongs with your prescriber or pharmacist.

09
Why HAVIT — Medication + Behavior Change, in One App
GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.
Part of the weight lost on GLP-1 therapy is lean mass rather than fat—anywhere from about 15% or less to 40–60% across trials (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.
That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).
HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.
Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).
Manage the medicine and the muscle — together. Start with HAVIT →
10
Related guides
- GLP-1 side effects: what's normal and when to worry
- GLP-1 tracker app: the complete guide
- GLP-1 diet: a 7-day meal plan
- Gamify weight loss: streaks & habits on GLP-1
- The GLP-1 Habit Report: what 1,090 users reveal
Get your questions answered and your habits tracked in one place — HAVIT.

Frequently asked questions
Are GLP-1 questions the same for Ozempic, Wegovy, Mounjaro, and Zepbound?
What should I eat first when appetite drops?
What do I do about a missed GLP-1 dose?
How long do GLP-1 side effects last?
Is a weight-loss plateau a sign the drug stopped working?
Can I prevent muscle loss on a GLP-1?
Do I have to stay on a GLP-1 forever?
Can an app answer my GLP-1 questions?
What is HAVIT?
HAVIT is an AI health partner built on metabolic science — it protects your muscle, wakes up your metabolism, and helps you keep a healthy, rebound-free body for the long run.
Unlike calorie-only trackers, HAVIT connects AI body-composition estimates, nutrition, hydration, sleep, steps, cycle, mood, and GLP-1 medication in one daily routine — so progress is measured by body composition, not just the number on the scale. Daily missions turn established behavior-change techniques into small repeatable actions, drawing on expertise from professionals formerly at Juvis Diet, one of Korea’s leading metabolic clinics.
In HAVIT’s own analysis of 1,090 GLP-1 users, people who logged consistently built stronger habits than the general user base. Read the GLP-1 Habit Report
Inside the app
- AI COACHA coach that reads your day.
- NUTRITIONLog meals in seconds.
- BODY INSIGHTSSee more than weight.
- DAILY MISSIONSBuild habits you can repeat.
- DAILY CHECK-INTell HAVI how today feels.
- TRACK EVERYTHINGFrom water to GLP-1
- MIND & RECOVERYFor the days willpower runs out.
HAVIT works with or without GLP-1 medication. It is a wellness app, not a medical device; body-composition results are estimates.
References
- WEGOVY (semaglutide) injection — Prescribing Information (2.4 Recommendations Regarding Missed Dose) accessdata.fda.gov
- ZEPBOUND (tirzepatide) injection — Prescribing Information (2.3 Recommendations Regarding Missed Dose) accessdata.fda.gov
- MOUNJARO (tirzepatide) injection — Prescribing Information accessdata.fda.gov
- GLP-1 Agonists my.clevelandclinic.org
- How Long To Take a GLP-1 for Weight Loss health.clevelandclinic.org
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension doi.org
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial doi.org
- Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies doi.org
- Effectiveness of Behaviorally Designed Gamification Interventions With Social Incentives for Increasing Physical Activity Among Overweight and Obese Adults Across the United States: The STEP UP Randomized Clinical Trial doi.org
- How are habits formed: Modelling habit formation in the real world doi.org
- Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement doi.org
- EMA — Wegovy EPAR product information (SmPC 4.2 missed dose, 4.6 breast-feeding) ema.europa.eu
- DailyMed — WEGOVY injection and tablets, prescribing information (version Jun 18, 2026) dailymed.nlm.nih.gov















